{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:07:03Z","timestamp":1789614423953,"version":"build-2803163510"},"reference-count":150,"publisher":"Harborside Press, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Central Nervous System Cancers provide multidisciplinary diagnostic workup, staging, and treatment recommendations for diffuse high-grade gliomas and medulloblastomas in children and adolescents. This article summarizes the studies and panel discussion that serve as the rationale for comprehensive care recommendations included in the NCCN Guidelines for Pediatric Central Nervous System Cancers.<\/jats:p>","DOI":"10.6004\/jnccn.2025.0012","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T09:13:20Z","timestamp":1741770800000},"page":"113-130","source":"Crossref","is-referenced-by-count":23,"title":["Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology"],"prefix":"10.6004","volume":"23","author":[{"given":"Amar","family":"Gajjar","sequence":"first","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejus","family":"Bale","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Bowers","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center\/Children\u2019s Medical Center Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Canan","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Chi","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Cluster","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Cohen","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center\/Johns Hopkins Children\u2019s Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Cole","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center\/Seattle Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Coven","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center\/ Riley Children\u2019s Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Darlington","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center\/UChicago Medicine Comer Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Dorris","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center\/Children\u2019s Hospital Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Elster","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center\/Rady Children\u2019s Hospital-San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Ermoian","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center\/Seattle Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Franson","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center\/C.S. Mott Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"George","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center\/UCSF Benioff Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Helgager","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center\/American Family Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Landi","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute\/Duke Children\u2019s Hospital & Health Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Lin","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center\/Children\u2019s Hospital & Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Metrock","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB\/Children\u2019s of Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronica","family":"Nanda","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Palmer","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute\/Nationwide Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Partap","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute\/Lucile Packard Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Plant","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University\/Ann & Robert H. Lurie Children\u2019s Hospital of Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Pruthi","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center\/Monroe Carrell Jr. Children\u2019s Hospital at Vanderbilt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center\/Roswell Park Oishei Children\u2019s Cancer and Blood Disorders Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Stearns","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute\/University Hospitals Rainbow Babies & Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Storm","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania\/Children\u2019s Hospital of Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Wang","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center\/UCLA Mattel Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo D.","family":"Wang","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Whipple","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah\/Primary Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafik","family":"Zaky","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"McMillian","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","article-title":"Key statistics for brain and spinal cord tumors in children","unstructured":"American Cancer Society. Key statistics for brain and spinal cord tumors in children. Accessed April 26, 2022. Available at: https:\/\/www.cancer.org\/cancer\/brain-spinal-cord-tumors-children\/about\/key-statistics.html"},{"key":"B2","article-title":"Risk of dying from cancer continues to drop at an accelerated pace","unstructured":"American Cancer Society. Risk of dying from cancer continues to drop at an accelerated pace. Accessed April 26, 2022. Available at: https:\/\/www.cancer.org\/latest-news\/facts-and-figures-2022.html"},{"key":"B3","series-title":"Neuro Oncol","first-page":"iii1","article-title":"CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014\u20132018","volume":"24","author":"Ostrom QT","year":"2022","unstructured":"Ostrom QT, Price M, Ryan K,  CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014\u20132018. Neuro Oncol 2022;24(Suppl 3):iii1\u201338."},{"key":"B4","series-title":"Neuro Oncol","first-page":"1231","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis DN","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P,  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231\u20131251."},{"key":"B5","series-title":"Cancer Discov","first-page":"331","article-title":"A summary of the inaugural WHO Classification of Pediatric Tumors: transitioning from the optical into the molecular era","volume":"12","author":"Pfister SM","year":"2022","unstructured":"Pfister SM, Reyes-Mugica M, Chan JKC,  A summary of the inaugural WHO Classification of Pediatric Tumors: transitioning from the optical into the molecular era. Cancer Discov 2022;12:331\u2013355."},{"key":"B6","series-title":"Cancer Metastasis Rev","first-page":"245","article-title":"Pediatric hemispheric high-grade glioma: targeting the future","volume":"39","author":"Coleman C","year":"2020","unstructured":"Coleman C, Stoller S, Grotzer M,  Pediatric hemispheric high-grade glioma: targeting the future. Cancer Metastasis Rev 2020;39:245\u2013260."},{"key":"B7","series-title":"Childhood Brain Tumors","author":"Subramanian S","year":"2024","unstructured":"Subramanian S, Ahmad T. Childhood Brain Tumors. Treasure Island, Florida: StatPearls Publishing; 2024."},{"key":"B8","series-title":"Neuro Oncol","first-page":"iv1","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013\u20132017","volume":"22","author":"Ostrom QT","year":"2020","unstructured":"Ostrom QT, Patil N, Cioffi G,  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013\u20132017. Neuro Oncol 2020;22(Suppl 2):iv1\u201396."},{"key":"B9","series-title":"Cancer Epidemiol Biomarkers Prev","first-page":"2716","article-title":"Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review","volume":"23","author":"Johnson KJ","year":"2014","unstructured":"Johnson KJ, Cullen J, Barnholtz-Sloan JS,  Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review. Cancer Epidemiol Biomarkers Prev 2014;23:2716\u20132736."},{"key":"B10","series-title":"J Child Neurol","first-page":"1526","article-title":"Neurooncology of familial cancer syndromes","volume":"24","author":"Hottinger AF","year":"2009","unstructured":"Hottinger AF, Khakoo Y. Neurooncology of familial cancer syndromes. J Child Neurol 2009;24:1526\u20131535."},{"key":"B11","series-title":"Pediatr Neurosurg","first-page":"271","article-title":"Tumors of central and peripheral nervous system associated with inherited genetic syndromes","volume":"48","author":"Stefanaki K","year":"2012","unstructured":"Stefanaki K, Alexiou GA, Stefanaki C, Prodromou N. Tumors of central and peripheral nervous system associated with inherited genetic syndromes. Pediatr Neurosurg 2012;48:271\u2013285."},{"key":"B12","series-title":"Clin Cancer Res","first-page":"3378","article-title":"Clinical updates and surveillance recommendations for DNA replication repair deficiency syndromes in children and young adults","volume":"30","author":"Das A","year":"2024","unstructured":"Das A, MacFarland SP, Meade J,  Clinical updates and surveillance recommendations for DNA replication repair deficiency syndromes in children and young adults. Clin Cancer Res 2024;30:3378\u20133387."},{"key":"B13","series-title":"Neuro Oncol","first-page":"1316","article-title":"Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review","volume":"14","author":"Braganza MZ","year":"2012","unstructured":"Braganza MZ, Kitahara CM, Berrington de Gonzalez A,  Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol 2012;14:1316\u20131324."},{"key":"B14","series-title":"Neuro Oncol","first-page":"1357","article-title":"Risk factors for childhood and adult primary brain tumors","volume":"21","author":"Ostrom QT","year":"2019","unstructured":"Ostrom QT, Adel Fahmideh M, Cote DJ,  Risk factors for childhood and adult primary brain tumors. Neuro Oncol 2019;21:1357\u20131375."},{"key":"B15","series-title":"Neurol Clin","first-page":"533","article-title":"Pediatric brain tumors","volume":"36","author":"Udaka YT","year":"2018","unstructured":"Udaka YT, Packer RJ. Pediatric brain tumors. Neurol Clin 2018;36:533\u2013556."},{"key":"B16","series-title":"Neuro Oncol","first-page":"1652","article-title":"Prospective evaluation of local control and late effects of conformal radiation therapy in children, adolescents, and young adults with high-grade glioma","volume":"16","author":"Vern-Gross TZ","year":"2014","unstructured":"Vern-Gross TZ, Schreiber JE, Broniscer A,  Prospective evaluation of local control and late effects of conformal radiation therapy in children, adolescents, and young adults with high-grade glioma. Neuro Oncol 2014;16:1652\u20131660."},{"key":"B17","series-title":"J Neurosurg Pediatr","first-page":"261","article-title":"Childhood brain tumors: current management, biological insights, and future directions","volume":"23","author":"Pollack IF","year":"2019","unstructured":"Pollack IF, Agnihotri S, Broniscer A. Childhood brain tumors: current management, biological insights, and future directions. J Neurosurg Pediatr 2019;23:261\u2013273."},{"key":"B18","series-title":"Front Neurol","first-page":"733323","article-title":"Advanced magnetic resonance imaging in pediatric glioblastomas","volume":"12","author":"Goncalves FG","year":"2021","unstructured":"Goncalves FG, Viaene AN, Vossough A. Advanced magnetic resonance imaging in pediatric glioblastomas. Front Neurol 2021;12:733323."},{"key":"B19","series-title":"Lancet Oncol","first-page":"e317","article-title":"Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","volume":"21","author":"Erker C","year":"2020","unstructured":"Erker C, Tamrazi B, Poussaint TY,  Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol 2020;21:e317\u2013329."},{"key":"B20","series-title":"Lancet Oncol","first-page":"e330","article-title":"Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","volume":"21","author":"Cooney TM","year":"2020","unstructured":"Cooney TM, Cohen KJ, Guimaraes CV,  Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol 2020;21:e330\u2013336."},{"key":"B21","series-title":"AJNR Am J Neuroradiol","first-page":"1581","article-title":"Response Assessment in Pediatric Neuro-Oncology: implementation and expansion of the RANO criteria in a randomized phase II trial of pediatric patients with newly diagnosed high-grade gliomas","volume":"37","author":"Jaspan T","year":"2016","unstructured":"Jaspan T, Morgan PS, Warmuth-Metz M,  Response Assessment in Pediatric Neuro-Oncology: implementation and expansion of the RANO criteria in a randomized phase II trial of pediatric patients with newly diagnosed high-grade gliomas. AJNR Am J Neuroradiol 2016;37:1581\u20131587."},{"key":"B22","series-title":"Neuro Oncol","first-page":"1188","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials","volume":"17","author":"Ellingson BM","year":"2015","unstructured":"Ellingson BM, Bendszus M, Boxerman J,  Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. Neuro Oncol 2015;17:1188\u20131198."},{"key":"B23","series-title":"Radiology","first-page":"486","article-title":"Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging","volume":"253","author":"Barajas RF, Jr","year":"2009","unstructured":"Barajas RF, Jr, Chang JS, Segal MR,  Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009;253:486\u2013496."},{"key":"B24","series-title":"Medicine (Baltimore)","first-page":"e6333","article-title":"The diagnostic performance of perfusion MRI for differentiating glioma recurrence from pseudoprogression: a meta-analysis","volume":"96","author":"Wan B","year":"2017","unstructured":"Wan B, Wang S, Tu M,  The diagnostic performance of perfusion MRI for differentiating glioma recurrence from pseudoprogression: a meta-analysis. Medicine (Baltimore) 2017;96:e6333."},{"key":"B25","series-title":"Eur Radiol","first-page":"4129","article-title":"Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis","volume":"27","author":"van Dijken BRJ","year":"2017","unstructured":"van Dijken BRJ, van Laar PJ, Holtman GA, van der Hoorn A. Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis. Eur Radiol 2017;27:4129\u20134144."},{"key":"B26","series-title":"Neuroradiology","first-page":"1143","article-title":"Perfusion magnetic resonance imaging in pediatric brain tumors","volume":"59","author":"Dallery F","year":"2017","unstructured":"Dallery F, Bouzerar R, Michel D,  Perfusion magnetic resonance imaging in pediatric brain tumors. Neuroradiology 2017;59:1143\u20131153."},{"key":"B27","series-title":"AJNR Am J Neuroradiol","first-page":"170","article-title":"Automated processing of dynamic contrast-enhanced MRI: correlation of advanced pharmacokinetic metrics with tumor grade in pediatric brain tumors","volume":"38","author":"Vajapeyam S","year":"2017","unstructured":"Vajapeyam S, Stamoulis C, Ricci K,  Automated processing of dynamic contrast-enhanced MRI: correlation of advanced pharmacokinetic metrics with tumor grade in pediatric brain tumors. AJNR Am J Neuroradiol 2017;38:170\u2013175."},{"key":"B28","series-title":"Eur Radiol","first-page":"2641","article-title":"Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot study","volume":"25","author":"Miyazaki K","year":"2015","unstructured":"Miyazaki K, Jerome NP, Collins DJ,  Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot study. Eur Radiol 2015;25:2641\u20132650."},{"key":"B29","series-title":"Neuroimage Clin","first-page":"262","article-title":"Assessment of blood-brain barrier disruption using dynamic contrast-enhanced MRI. A systematic review","volume":"6","author":"Heye AK","year":"2014","unstructured":"Heye AK, Culling RD, Vald\u00e9s Hern\u00e1ndez MDC,  Assessment of blood-brain barrier disruption using dynamic contrast-enhanced MRI. A systematic review. Neuroimage Clin 2014;6:262\u2013274."},{"key":"B30","series-title":"Radiology","first-page":"933","article-title":"Brain gliomas: multicenter standardized assessment of dynamic contrast-enhanced and dynamic susceptibility contrast MR images","volume":"287","author":"Anzalone N","year":"2018","unstructured":"Anzalone N, Castellano A, Cadioli M,  Brain gliomas: multicenter standardized assessment of dynamic contrast-enhanced and dynamic susceptibility contrast MR images. Radiology 2018;287:933\u2013943."},{"key":"B31","series-title":"Radiology","first-page":"553","article-title":"Arterial spin labeling to predict brain tumor grading in children: correlations between histopathologic vascular density and perfusion MR imaging","volume":"281","author":"Dangouloff-Ros V","year":"2016","unstructured":"Dangouloff-Ros V, Deroulers C, Foissac F,  Arterial spin labeling to predict brain tumor grading in children: correlations between histopathologic vascular density and perfusion MR imaging. Radiology 2016;281:553\u2013566."},{"key":"B32","series-title":"Neuroimage Clin","first-page":"101696","article-title":"Arterial spin labelling and diffusion-weighted imaging in paediatric brain tumours","volume":"22","author":"Hales PW","year":"2019","unstructured":"Hales PW, d\u2019Arco F, Cooper J,  Arterial spin labelling and diffusion-weighted imaging in paediatric brain tumours. Neuroimage Clin 2019;22:101696."},{"key":"B33","series-title":"AJNR Am J Neuroradiol","first-page":"395","article-title":"Arterial spin-labeled perfusion of pediatric brain tumors","volume":"35","author":"Yeom KW","year":"2014","unstructured":"Yeom KW, Mitchell LA, Lober RM,  Arterial spin-labeled perfusion of pediatric brain tumors. AJNR Am J Neuroradiol 2014;35:395\u2013401."},{"key":"B34","series-title":"AJNR Am J Neuroradiol","first-page":"1228","article-title":"Arterial spin-labeling in routine clinical practice, part 1: technique and artifacts","volume":"29","author":"Deibler AR","year":"2008","unstructured":"Deibler AR, Pollock JM, Kraft RA,  Arterial spin-labeling in routine clinical practice, part 1: technique and artifacts. AJNR Am J Neuroradiol 2008;29:1228\u20131234."},{"key":"B35","series-title":"Pediatr Neurosurg","first-page":"298","article-title":"Role of dynamic contrast-enhanced perfusion magnetic resonance imaging in grading of pediatric brain tumors on 3T","volume":"52","author":"Gupta PK","year":"2017","unstructured":"Gupta PK, Saini J, Sahoo P,  Role of dynamic contrast-enhanced perfusion magnetic resonance imaging in grading of pediatric brain tumors on 3T. Pediatr Neurosurg 2017;52:298\u2013305."},{"key":"B36","series-title":"Eur J Radiol","first-page":"2181","article-title":"Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: a systematic review and meta-analysis","volume":"83","author":"Zhang H","year":"2014","unstructured":"Zhang H, Ma L, Wang Q,  Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: a systematic review and meta-analysis. Eur J Radiol 2014;83:2181\u20132189."},{"key":"B37","article-title":"Tests for brain and spinal cord tumors in children","unstructured":"American Cancer Society. Tests for brain and spinal cord tumors in children. Accessed July 25, 2022. Available at: https:\/\/www.cancer.org\/cancer\/brain-spinal-cord-tumors-children\/detection-diagnosis-staging\/how-diagnosed.html"},{"key":"B38","series-title":"Cancer Cell","first-page":"569","article-title":"Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas","volume":"37","author":"Ryall S","year":"2020","unstructured":"Ryall S, Zapotocky M, Fukuoka K,  Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 2020;37:569\u2013583.e5."},{"key":"B39","series-title":"Cancer Discov","first-page":"942","article-title":"Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes","volume":"10","author":"Clarke M","year":"2020","unstructured":"Clarke M, Mackay A, Ismer B,  Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer Discov 2020;10:942\u2013963."},{"key":"B40","series-title":"Nat Commun","first-page":"4343","article-title":"Alterations in ALK\/ROS1\/NTRK\/MET drive a group of infantile hemispheric gliomas","volume":"10","author":"Guerreiro Stucklin AS","year":"2019","unstructured":"Guerreiro Stucklin AS, Ryall S, Fukuoka K,  Alterations in ALK\/ROS1\/NTRK\/MET drive a group of infantile hemispheric gliomas. Nat Commun 2019;10:4343."},{"key":"B41","series-title":"Oncologist","first-page":"1478","article-title":"Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures","volume":"22","author":"Johnson A","year":"2017","unstructured":"Johnson A, Severson E, Gay L,  Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist 2017;22:1478\u20131490."},{"key":"B42","series-title":"Acta Neuropathol","first-page":"683","article-title":"cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation","volume":"137","author":"Ellison DW","year":"2019","unstructured":"Ellison DW, Hawkins C, Jones DTW,  cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation. Acta Neuropathol 2019;137:683\u2013687."},{"key":"B43","series-title":"Brain Pathol","first-page":"844","article-title":"cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading","volume":"30","author":"Louis DN","year":"2020","unstructured":"Louis DN, Wesseling P, Aldape K,  cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol 2020;30:844\u2013856."},{"key":"B44","series-title":"N Engl J Med","first-page":"2336","article-title":"Germline mutations in predisposition genes in pediatric cancer","volume":"373","author":"Zhang J","year":"2015","unstructured":"Zhang J, Walsh MF, Wu G,  Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 2015;373:2336\u20132346."},{"key":"B45","series-title":"Nat Commun","first-page":"2206","article-title":"Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors","volume":"11","author":"Akhavanfard S","year":"2020","unstructured":"Akhavanfard S, Padmanabhan R, Yehia L,  Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors. Nat Commun 2020;11:2206."},{"key":"B46","series-title":"Prog Neurol Surg","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000464437","article-title":"Surgery of intracranial gliomas in children","volume":"30","author":"Balogun JA","year":"2018","unstructured":"Balogun JA, Rutka JT. Surgery of intracranial gliomas in children. Prog Neurol Surg 2018;30:204\u2013217."},{"key":"B47","series-title":"Neuro Oncol","first-page":"197","article-title":"The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience","volume":"5","author":"Pollack IF","year":"2003","unstructured":"Pollack IF, Boyett JM, Yates AJ,  The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. Neuro Oncol 2003;5:197\u2013207."},{"key":"B48","series-title":"J Clin Oncol","first-page":"112","article-title":"Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group","volume":"13","author":"Finlay JL","year":"1995","unstructured":"Finlay JL, Boyett JM, Yates AJ,  Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol 1995;13:112\u2013123."},{"key":"B49","series-title":"J Neurosurg Pediatr","first-page":"160","article-title":"High-grade gliomas in children and adolescents: is there a role for reoperation?","volume":"27","author":"Silva da Costa MD","year":"2021","unstructured":"Silva da Costa MD, Camargo NC, Dastoli PA,  High-grade gliomas in children and adolescents: is there a role for reoperation? J Neurosurg Pediatr 2021;27:160\u2013169."},{"key":"B50","series-title":"Neurosurgery","first-page":"443","article-title":"Sex, age, anatomic location, and extent of resection influence outcomes in children with high-grade glioma","volume":"77","author":"McCrea HJ","year":"2015","unstructured":"McCrea HJ, Bander ED, Venn RA,  Sex, age, anatomic location, and extent of resection influence outcomes in children with high-grade glioma. Neurosurgery 2015;77:443\u2013452."},{"key":"B51","series-title":"Cancers (Basel)","first-page":"2062","article-title":"High-grade gliomas in children-a multi-institutional polish study","volume":"13","author":"Napieralska A","year":"2021","unstructured":"Napieralska A, Krzywon A, Mizia-Malarz A,  High-grade gliomas in children-a multi-institutional polish study. Cancers (Basel) 2021;13:2062."},{"key":"B52","series-title":"Cancer","first-page":"705","article-title":"Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol","volume":"116","author":"Wolff JE","year":"2010","unstructured":"Wolff JE, Driever PH, Erdlenbruch B,  Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer 2010;116:705\u2013712."},{"key":"B53","series-title":"Anticancer Res","first-page":"3773","article-title":"Improved survival after gross total resection of malignant gliomas in pediatric patients from the HIT-GBM studies","volume":"26","author":"Kramm CM","year":"2006","unstructured":"Kramm CM, Wagner S, Van Gool S,  Improved survival after gross total resection of malignant gliomas in pediatric patients from the HIT-GBM studies. Anticancer Res 2006;26:3773\u20133779."},{"key":"B54","series-title":"JAMA Netw Open","first-page":"e2226551","article-title":"Extent of tumor resection and survival in pediatric patients with high-grade gliomas: a systematic review and meta-analysis","volume":"5","author":"Hatoum R","year":"2022","unstructured":"Hatoum R, Chen JS, Lavergne P,  Extent of tumor resection and survival in pediatric patients with high-grade gliomas: a systematic review and meta-analysis. JAMA Netw Open 2022;5:e2226551."},{"key":"B55","series-title":"CNS Oncol","first-page":"61","article-title":"Treatment options for recurrent high-grade gliomas","volume":"6","author":"Birk HS","year":"2017","unstructured":"Birk HS, Han SJ, Butowski NA. Treatment options for recurrent high-grade gliomas. CNS Oncol 2017;6:61\u201370."},{"key":"B56","series-title":"Cochrane Database Syst Rev","first-page":"CD007286","article-title":"Antiepileptic drugs as prophylaxis for postcraniotomy seizures","volume":"4","author":"Greenhalgh J","year":"2020","unstructured":"Greenhalgh J, Weston J, Dundar Y,  Antiepileptic drugs as prophylaxis for postcraniotomy seizures. Cochrane Database Syst Rev 2020;4:CD007286."},{"key":"B57","series-title":"Neuro Oncol","first-page":"1442","article-title":"Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children\u2019s Oncology Group ACNS0423 study","volume":"18","author":"Jakacki RI","year":"2016","unstructured":"Jakacki RI, Cohen KJ, Buxton A,  Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children\u2019s Oncology Group ACNS0423 study. Neuro Oncol 2016;18:1442\u20131450."},{"key":"B58","series-title":"Neuro Oncol","first-page":"317","article-title":"Temozolomide in the treatment of high-grade gliomas in children: a report from the Children\u2019s Oncology Group","volume":"13","author":"Cohen KJ","year":"2011","unstructured":"Cohen KJ, Pollack IF, Zhou T,  Temozolomide in the treatment of high-grade gliomas in children: a report from the Children\u2019s Oncology Group. Neuro Oncol 2011;13:317\u2013323."},{"key":"B59","series-title":"Radiation","first-page":"218","article-title":"Proton therapy and gliomas: a systematic review","volume":"1","author":"Chambrelant I","year":"2021","unstructured":"Chambrelant I, Eber J, Antoni D,  Proton therapy and gliomas: a systematic review. Radiation 2021;1:218\u2013233."},{"key":"B60","series-title":"Neurol Med Chir (Tokyo)","first-page":"343","article-title":"Proton beam therapy for pediatric brain tumor","volume":"57","author":"Mizumoto M","year":"2017","unstructured":"Mizumoto M, Oshiro Y, Yamamoto T,  Proton beam therapy for pediatric brain tumor. Neurol Med Chir (Tokyo) 2017;57:343\u2013355."},{"key":"B61","series-title":"Strahlenther Onkol","first-page":"10","article-title":"Conformal proton radiation therapy for pediatric low-grade astrocytomas","volume":"178","author":"Hug EB","year":"2002","unstructured":"Hug EB, Muenter MW, Archambeau JO,  Conformal proton radiation therapy for pediatric low-grade astrocytomas. Strahlenther Onkol 2002;178:10\u201317."},{"key":"B62","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1060","article-title":"Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas","volume":"89","author":"Greenberger BA","year":"2014","unstructured":"Greenberger BA, Pulsifer MB, Ebb DH,  Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys 2014;89:1060\u20131068."},{"key":"B63","series-title":"Radiat Oncol","first-page":"189","article-title":"First experiences in treatment of low-grade glioma grade I and II with proton therapy","volume":"7","author":"Hauswald H","year":"2012","unstructured":"Hauswald H, Rieken S, Ecker S,  First experiences in treatment of low-grade glioma grade I and II with proton therapy. Radiat Oncol 2012;7:189."},{"key":"B64","series-title":"World Neurosurg","first-page":"658","article-title":"Gamma knife surgery versus reoperation for recurrent glioblastoma multiforme","volume":"78","author":"Skeie BS","year":"2012","unstructured":"Skeie BS, Enger PO, Brogger J,  Gamma knife surgery versus reoperation for recurrent glioblastoma multiforme. World Neurosurg 2012;78:658\u2013669."},{"key":"B65","series-title":"Radiat Oncol","first-page":"36","article-title":"Current status and recent advances in reirradiation of glioblastoma","volume":"16","author":"Minniti G","year":"2021","unstructured":"Minniti G, Niyazi M, Alongi F,  Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol 2021;16:36."},{"key":"B66","series-title":"J Neurooncol","first-page":"255","article-title":"Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of radiation therapy in the management of progressive and recurrent glioblastoma in adults","volume":"158","author":"Ziu M","year":"2022","unstructured":"Ziu M, Goyal S, Olson JJ. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of radiation therapy in the management of progressive and recurrent glioblastoma in adults. J Neurooncol 2022;158:255\u2013264."},{"key":"B67","series-title":"Cancers (Basel)","first-page":"257","article-title":"Radiation therapy for the treatment of recurrent glioblastoma: an overview","volume":"4","author":"Amelio D","year":"2012","unstructured":"Amelio D, Amichetti M. Radiation therapy for the treatment of recurrent glioblastoma: an overview. Cancers (Basel) 2012;4:257\u2013280."},{"key":"B68","series-title":"Neurosurgery","first-page":"275","article-title":"Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme","volume":"36","author":"Shrieve DC","year":"1995","unstructured":"Shrieve DC, Alexander E, Wen PY,  Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 1995;36:275\u2013282."},{"key":"B69","series-title":"Pediatr Blood Cancer","first-page":"e27881","article-title":"Repeat irradiation for children with supratentorial high-grade glioma","volume":"66","author":"Tsang DS","year":"2019","unstructured":"Tsang DS, Oliveira C, Bouffet E,  Repeat irradiation for children with supratentorial high-grade glioma. Pediatr Blood Cancer 2019;66:e27881."},{"key":"B70","series-title":"Neuro Oncol","first-page":"290","article-title":"A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the pediatric brain tumor consortium","volume":"13","author":"Pollack IF","year":"2011","unstructured":"Pollack IF, Stewart CF, Kocak M,  A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the pediatric brain tumor consortium. Neuro Oncol 2011;13:290\u2013297."},{"key":"B71","series-title":"J Clin Oncol","first-page":"3431","article-title":"Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children\u2019s Cancer Group","volume":"20","author":"Jennings MT","year":"2002","unstructured":"Jennings MT, Sposto R, Boyett JM,  Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children\u2019s Cancer Group. J Clin Oncol 2002;20:3431\u20133437."},{"key":"B72","series-title":"Neuro Oncol","first-page":"410","article-title":"Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children\u2019s Oncology Group","volume":"13","author":"Cohen KJ","year":"2011","unstructured":"Cohen KJ, Heideman RL, Zhou T,  Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children\u2019s Oncology Group. Neuro Oncol 2011;13:410\u2013416."},{"key":"B73","series-title":"Int J Radiat Oncol Biol Phys","first-page":"e55","article-title":"Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children\u2019s oncology group phase 2 study","volume":"85","author":"Bradley KA","year":"2013","unstructured":"Bradley KA, Zhou T, McNall-Knapp RY,  Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children\u2019s oncology group phase 2 study. Int J Radiat Oncol Biol Phys 2013;85:e55\u201360."},{"key":"B74","series-title":"Int J Radiat Oncol Biol Phys","first-page":"197","article-title":"Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study","volume":"27","author":"Freeman CR","year":"1993","unstructured":"Freeman CR, Krischer JP, Sanford RA,  Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys 1993;27:197\u2013206."},{"key":"B75","series-title":"Adv Radiat Oncol","first-page":"520","article-title":"Role of radiation therapy in the management of diffuse intrinsic pontine glioma: a systematic review","volume":"4","author":"Gallitto M","year":"2019","unstructured":"Gallitto M, Lazarev S, Wasserman I,  Role of radiation therapy in the management of diffuse intrinsic pontine glioma: a systematic review. Adv Radiat Oncol 2019;4:520\u2013531."},{"key":"B76","series-title":"Radiother Oncol","first-page":"35","article-title":"Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial","volume":"111","author":"Zaghloul MS","year":"2014","unstructured":"Zaghloul MS, Eldebawy E, Ahmed S,  Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial. Radiother Oncol 2014;111:35\u201340."},{"key":"B77","series-title":"Cochrane Database Syst Rev","first-page":"CD010439","article-title":"Radiotherapy for diffuse brainstem glioma in children and young adults","volume":"2016","author":"Hu X","year":"2016","unstructured":"Hu X, Fang Y, Hui X,  Radiotherapy for diffuse brainstem glioma in children and young adults. Cochrane Database Syst Rev 2016;2016:CD010439."},{"key":"B78","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1008","article-title":"Hypofractionated radiation for pediatric diffuse intrinsic pontine glioma (DIPG): younger children have better survival","volume":"101","author":"Zaghloul MS","year":"2018","unstructured":"Zaghloul MS, Akoush H, Ahmed S,  Hypofractionated radiation for pediatric diffuse intrinsic pontine glioma (DIPG): younger children have better survival. Int J Radiat Oncol Biol Phys 2018;101:1008\u20131009."},{"key":"B79","series-title":"Int J Radiat Oncol Biol Phys","first-page":"360","article-title":"Hypofractionated radiation therapy for diffuse intrinsic pontine glioma: a noninferiority randomized study including 253 children","volume":"113","author":"Zaghloul MS","year":"2022","unstructured":"Zaghloul MS, Nasr A, Tolba M,  Hypofractionated radiation therapy for diffuse intrinsic pontine glioma: a noninferiority randomized study including 253 children. Int J Radiat Oncol Biol Phys 2022;113:360\u2013368."},{"key":"B80","series-title":"Pract Radiat Oncol","first-page":"86","article-title":"Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a systematic review of the reirradiation literature","volume":"7","author":"Freese C","year":"2017","unstructured":"Freese C, Takiar V, Fouladi M,  Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a systematic review of the reirradiation literature. Pract Radiat Oncol 2017;7:86\u201392."},{"key":"B81","series-title":"Childs Nerv Syst","first-page":"739","article-title":"Reirradiation for diffuse intrinsic pontine glioma: a systematic review and meta-analysis","volume":"35","author":"Lu VM","year":"2019","unstructured":"Lu VM, Welby JP, Mahajan A,  Reirradiation for diffuse intrinsic pontine glioma: a systematic review and meta-analysis. Childs Nerv Syst 2019;35:739\u2013746."},{"key":"B82","series-title":"Int J Radiat Oncol Biol Phys","first-page":"144","article-title":"A phase 1\/2 trial of reirradiation for diffuse intrinsic pontine glioma","volume":"104","author":"Amsbaugh MJ","year":"2019","unstructured":"Amsbaugh MJ, Mahajan A, Thall PF,  A phase 1\/2 trial of reirradiation for diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 2019;104:144\u2013148."},{"key":"B83","series-title":"J Neurooncol","first-page":"245","article-title":"Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience","volume":"28","author":"Duffner PK","year":"1996","unstructured":"Duffner PK, Krischer JP, Burger PC,  Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. J Neurooncol 1996;28:245\u2013256."},{"key":"B84","series-title":"Pediatr Blood Cancer","first-page":"1806","article-title":"Outcome of young children with high-grade glioma treated with irradiation-avoiding intensive chemotherapy regimens: final report of the head start II and III trials","volume":"63","author":"Espinoza JC","year":"2016","unstructured":"Espinoza JC, Haley K, Patel N,  Outcome of young children with high-grade glioma treated with irradiation-avoiding intensive chemotherapy regimens: final report of the head start II and III trials. Pediatr Blood Cancer 2016;63:1806\u20131813."},{"key":"B85","series-title":"Oncotarget","first-page":"1942","article-title":"Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)","volume":"11","author":"Nicolaides T","year":"2020","unstructured":"Nicolaides T, Nazemi KJ, Crawford J,  Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget 2020;11:1942\u20131952."},{"key":"B86","series-title":"J Cancer Res Clin Oncol","first-page":"89","article-title":"Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification","volume":"142","author":"Gierke M","year":"2016","unstructured":"Gierke M, Sperveslage J, Schwab D,  Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification. J Cancer Res Clin Oncol 2016;142:89\u2013100."},{"key":"B87","series-title":"Am J Surg Pathol","first-page":"685","article-title":"Epithelioid GBMs show a high percentage of BRAF V600E mutation","volume":"37","author":"Kleinschmidt-DeMasters BK","year":"2013","unstructured":"Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 2013;37:685\u2013698."},{"key":"B88","series-title":"Acta Neuropathol","first-page":"397","article-title":"Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma","volume":"121","author":"Schindler G","year":"2011","unstructured":"Schindler G, Capper D, Meyer J,  Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397\u2013405."},{"key":"B89","series-title":"Nature","first-page":"431","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou G","year":"2010","unstructured":"Hatzivassiliou G, Song K, Yen I,  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431\u2013435."},{"key":"B90","series-title":"Nature","first-page":"427","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos PI","year":"2010","unstructured":"Poulikakos PI, Zhang C, Bollag G,  RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427\u2013430."},{"key":"B91","series-title":"N Engl J Med","first-page":"207","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su F","year":"2012","unstructured":"Su F, Viros A, Milagre C,  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207\u2013215."},{"key":"B92","series-title":"Oncotarget","first-page":"551","article-title":"Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy","volume":"10","author":"Toll SA","year":"2019","unstructured":"Toll SA, Tran HN, Cotter J,  Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy. Oncotarget 2019;10:551\u2013557."},{"key":"B93","series-title":"Pediatr Blood Cancer","first-page":"e26969","article-title":"Response to the BRAF\/MEK inhibitors dabrafenib\/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib","volume":"65","author":"Marks AM","year":"2018","unstructured":"Marks AM, Bindra RS, DiLuna ML,  Response to the BRAF\/MEK inhibitors dabrafenib\/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib. Pediatr Blood Cancer 2018;65:e26969."},{"key":"B94","series-title":"BMC Cancer","first-page":"258","article-title":"Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy","volume":"14","author":"Robinson GW","year":"2014","unstructured":"Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 2014;14:258."},{"key":"B95","series-title":"Pediatr Blood Cancer","first-page":"1101","article-title":"Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas","volume":"61","author":"Bautista F","year":"2014","unstructured":"Bautista F, Paci A, Minard-Colin V,  Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer 2014;61:1101\u20131103."},{"key":"B96","series-title":"Mod Pathol","first-page":"147","article-title":"Molecular characterization of cancers with NTRK gene fusions","volume":"32","author":"Gatalica Z","year":"2019","unstructured":"Gatalica Z, Xiu J, Swensen J, Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol 2019;32:147\u2013153."},{"key":"B97","series-title":"ESMO Open","first-page":"e000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu A","year":"2016","unstructured":"Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 2016;1:e000023."},{"key":"B98","series-title":"N Engl J Med","first-page":"731","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon A","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S,  Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731\u2013739."},{"key":"B99","series-title":"Neuro Oncol","first-page":"1776","article-title":"Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)","volume":"24","author":"Desai AV","year":"2022","unstructured":"Desai AV, Robinson GW, Gauvain K,  Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol 2022;24:1776\u20131789."},{"key":"B100","series-title":"Lancet Oncol","first-page":"705","article-title":"Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study","volume":"19","author":"Laetsch TW","year":"2018","unstructured":"Laetsch TW, DuBois SG, Mascarenhas L,  Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study. Lancet Oncol 2018;19:705\u2013714."},{"key":"B101","series-title":"Lancet Oncol","first-page":"271","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele RC","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L,  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271\u2013282."},{"key":"B102","article-title":"FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors","unstructured":"Food and Drug Administration. FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors. Accessed July 12, 2024. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-repotrectinib-adult-and-pediatric-patients-ntrk-gene-fusion-positive"},{"key":"B103","series-title":"Ann Oncol","first-page":"S787","article-title":"1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon BJ","year":"2023","unstructured":"Solomon BJ, Drilon A, Lin JJ,  1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial. Ann Oncol 2023;34(Suppl 2):S787\u2013788."},{"key":"B104","series-title":"N Engl J Med","first-page":"761","article-title":"Lorlatinib in a child with ALK- fusion-positive high-grade glioma","volume":"385","author":"Bagchi A","year":"2021","unstructured":"Bagchi A, Orr BA, Campagne O,  Lorlatinib in a child with ALK- fusion-positive high-grade glioma. N Engl J Med 2021;385:761\u2013763."},{"key":"B105","series-title":"Cancer Res","first-page":"Abstract CT039","article-title":"Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: data from the iMATRIX Alectinib Phase I\/II open-label, multi-center study","volume":"84","author":"Doz F","year":"2024","unstructured":"Doz F, Casanova M, Koh K-N,  Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: data from the iMATRIX Alectinib Phase I\/II open-label, multi-center study. Cancer Res 2024;84(Suppl 7):Abstract CT039."},{"key":"B106","series-title":"J Clin Oncol","first-page":"2206","article-title":"Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency","volume":"34","author":"Bouffet E","year":"2016","unstructured":"Bouffet E, Larouche V, Campbell BB,  Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 2016;34:2206\u20132211."},{"key":"B107","series-title":"Pediatr Blood Cancer","first-page":"e27389","article-title":"Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency","volume":"65","author":"Larouche V","year":"2018","unstructured":"Larouche V, Atkinson J, Albrecht S,  Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency. Pediatr Blood Cancer 2018;65:e27389."},{"key":"B108","series-title":"J Neurooncol","first-page":"113","article-title":"Immune checkpoint inhibition for pediatric patients with recurrent\/refractory CNS tumors: a single institution experience","volume":"149","author":"Cacciotti C","year":"2020","unstructured":"Cacciotti C, Choi J, Alexandrescu S,  Immune checkpoint inhibition for pediatric patients with recurrent\/refractory CNS tumors: a single institution experience. J Neurooncol 2020;149:113\u2013122."},{"key":"B109","series-title":"Med Pediatr Oncol","first-page":"28","article-title":"Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors","volume":"29","author":"Needle MN","year":"1997","unstructured":"Needle MN, Molloy PT, Geyer JR,  Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 1997;29:28\u201332."},{"key":"B110","series-title":"J Clin Oncol","first-page":"951","article-title":"Phase II, open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma","volume":"36","author":"Grill J","year":"2018","unstructured":"Grill J, Massimino M, Bouffet E,  Phase II, open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol 2018;36:951\u2013958."},{"key":"B111","series-title":"Neuro Oncol","first-page":"vi1","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017\u20132021","volume":"26","author":"Price M","year":"2024","unstructured":"Price M, Ballard C, Benedetti J,  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017\u20132021. Neuro Oncol 2024;26(Suppl 6):vi1\u201385."},{"key":"B112","series-title":"Lancet Oncol","first-page":"484","article-title":"Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis","volume":"17","author":"Thompson EM","year":"2016","unstructured":"Thompson EM, Hielscher T, Bouffet E,  Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol 2016;17:484\u2013495."},{"key":"B113","series-title":"Acta Neuropathol","first-page":"465","article-title":"Molecular subgroups of medulloblastoma: the current consensus","volume":"123","author":"Taylor MD","year":"2012","unstructured":"Taylor MD, Northcott PA, Korshunov A,  Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012;123:465\u2013472."},{"key":"B114","series-title":"Acta Neuropathol","first-page":"473","article-title":"Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas","volume":"123","author":"Kool M","year":"2012","unstructured":"Kool M, Korshunov A, Remke M,  Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012;123:473\u2013484."},{"key":"B115","series-title":"Lancet Oncol","first-page":"958","article-title":"Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study","volume":"18","author":"Schwalbe EC","year":"2017","unstructured":"Schwalbe EC, Lindsey JC, Nakjang S,  Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol 2017;18:958\u2013971."},{"key":"B116","series-title":"Front Oncol","first-page":"566822","article-title":"Cancer predisposition syndromes and medulloblastoma in the molecular era","volume":"10","author":"Carta R","year":"2020","unstructured":"Carta R, Del Baldo G, Miele E,  Cancer predisposition syndromes and medulloblastoma in the molecular era. Front Oncol 2020;10:566822."},{"key":"B117","series-title":"Lancet Oncol","first-page":"785","article-title":"Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort","volume":"19","author":"Waszak SM","year":"2018","unstructured":"Waszak SM, Northcott PA, Buchhalter I,  Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 2018;19:785\u2013798."},{"key":"B118","series-title":"Neurochirurgie","first-page":"6","article-title":"Imaging features of medulloblastoma: conventional imaging, diffusion-weighted imaging, perfusion-weighted imaging, and spectroscopy: from general features to subtypes and characteristics","volume":"67","author":"Dangouloff-Ros V","year":"2021","unstructured":"Dangouloff-Ros V, Varlet P, Levy R,  Imaging features of medulloblastoma: conventional imaging, diffusion-weighted imaging, perfusion-weighted imaging, and spectroscopy: from general features to subtypes and characteristics. Neurochirurgie 2021;67:6\u201313."},{"key":"B119","series-title":"Pediatr Blood Cancer","first-page":"e30150","article-title":"Imaging of pediatric spine and spinal cord tumors: a COG diagnostic imaging committee\/SPR oncology committee\/ASPNR white paper","volume":"70","author":"Rogers SN","year":"2023","unstructured":"Rogers SN, Udayasankar U, Pruthi S,  Imaging of pediatric spine and spinal cord tumors: a COG diagnostic imaging committee\/SPR oncology committee\/ASPNR white paper. Pediatr Blood Cancer 2023;70(Suppl 4):e30150."},{"key":"B120","series-title":"J Neuroimaging","first-page":"503","article-title":"Pediatric posterior fossa medulloblastoma: the role of diffusion imaging in identifying molecular groups","volume":"30","author":"Reddy N","year":"2020","unstructured":"Reddy N, Ellison DW, Soares BP,  Pediatric posterior fossa medulloblastoma: the role of diffusion imaging in identifying molecular groups. J Neuroimaging 2020;30:503\u2013511."},{"key":"B121","series-title":"AJNR Am J Neuroradiol","first-page":"154","article-title":"MR imaging-based radiomic signatures of distinct molecular subgroups of medulloblastoma","volume":"40","author":"Iv M","year":"2019","unstructured":"Iv M, Zhou M, Shpanskaya K,  MR imaging-based radiomic signatures of distinct molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol 2019;40:154\u2013161."},{"key":"B122","series-title":"Clin Nucl Med","first-page":"530","article-title":"Demonstration of diffuse leptomeningeal metastasis in a treated case of medulloblastoma with F-18 FDG PET\/CT","volume":"34","author":"Tripathi M","year":"2009","unstructured":"Tripathi M, Jain N, Jaimini A,  Demonstration of diffuse leptomeningeal metastasis in a treated case of medulloblastoma with F-18 FDG PET\/CT. Clin Nucl Med 2009;34:530\u2013532."},{"key":"B123","series-title":"Neurosurgery","first-page":"1280","article-title":"[18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma","volume":"55","author":"Gururangan S","year":"2004","unstructured":"Gururangan S, Hwang E, Herndon JE,  [18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. Neurosurgery 2004;55:1280\u20131288."},{"key":"B124","series-title":"Radiology","first-page":"406","article-title":"MRI radiogenomics of pediatric medulloblastoma: a multicenter study","volume":"304","author":"Zhang M","year":"2022","unstructured":"Zhang M, Wong SW, Wright JN,  MRI radiogenomics of pediatric medulloblastoma: a multicenter study. Radiology 2022;304:406\u2013416."},{"key":"B125","series-title":"Pediatr Blood Cancer","first-page":"e26472","article-title":"The clinical significance of equivocal findings on spinal MRI in children with medulloblastoma","volume":"64","author":"Bennett J","year":"2017","unstructured":"Bennett J, Ashmawy R, Ramaswamy V,  The clinical significance of equivocal findings on spinal MRI in children with medulloblastoma. Pediatr Blood Cancer 2017;64:e26472."},{"key":"B126","series-title":"Acta Neuropathol","first-page":"381","article-title":"Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH\/WNT molecular subgroups","volume":"121","author":"Ellison DW","year":"2011","unstructured":"Ellison DW, Dalton J, Kocak M,  Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH\/WNT molecular subgroups. Acta Neuropathol 2011;121:381\u2013396."},{"key":"B127","series-title":"J Clin Oncol","first-page":"2927","article-title":"Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma","volume":"31","author":"Zhukova N","year":"2013","unstructured":"Zhukova N, Ramaswamy V, Remke M,  Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013;31:2927\u20132935."},{"key":"B128","series-title":"Nature","first-page":"311","article-title":"The whole-genome landscape of medulloblastoma subtypes","volume":"547","author":"Northcott PA","year":"2017","unstructured":"Northcott PA, Buchhalter I, Morrissy AS,  The whole-genome landscape of medulloblastoma subtypes. Nature 2017;547:311\u2013317."},{"key":"B129","series-title":"Neurosurgery","first-page":"265","article-title":"Effects of medulloblastoma resections on outcome in children: a report from the Children\u2019s Cancer Group","volume":"38","author":"Albright AL","year":"1996","unstructured":"Albright AL, Wisoff JH, Zeltzer PM,  Effects of medulloblastoma resections on outcome in children: a report from the Children\u2019s Cancer Group. Neurosurgery 1996;38:265\u2013271."},{"key":"B130","series-title":"J Clin Oncol","first-page":"832","article-title":"Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children\u2019s Cancer Group 921 randomized phase III study","volume":"17","author":"Zeltzer PM","year":"1999","unstructured":"Zeltzer PM, Boyett JM, Finlay JL,  Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children\u2019s Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17:832\u2013845."},{"key":"B131","series-title":"Neurosurgery","first-page":"478","article-title":"Predisposition of wingless subgroup medulloblastoma for primary tumor hemorrhage","volume":"86","author":"Reisinger D","year":"2020","unstructured":"Reisinger D, Gojo J, Kasprian G,  Predisposition of wingless subgroup medulloblastoma for primary tumor hemorrhage. Neurosurgery 2020;86:478\u2013484."},{"key":"B132","series-title":"Neurosurgery","first-page":"1050","article-title":"Reoperation for medulloblastoma prior to adjuvant therapy","volume":"84","author":"Patel P","year":"2019","unstructured":"Patel P, Wallace D, Boop FA,  Reoperation for medulloblastoma prior to adjuvant therapy. Neurosurgery 2019;84:1050\u20131058."},{"key":"B133","series-title":"J Neurooncol","first-page":"i104","article-title":"MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT\/non-SHH medulloblastoma despite highly intensified chemotherapy \u2013 results of the MET-HIT2000-BIS4 trial","volume":"24","author":"Mynarek M","year":"2022","unstructured":"Mynarek M, Goschzik T, Kool M,  MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT\/non-SHH medulloblastoma despite highly intensified chemotherapy \u2013 results of the MET-HIT2000-BIS4 trial. J Neurooncol 2022;24(Suppl 1):i104."},{"key":"B134","series-title":"Clin Cancer Res","first-page":"5031","article-title":"A pilot study omitting radiation in the treatment of children with newly diagnosed WNT-activated medulloblastoma","volume":"29","author":"Cohen KJ","year":"2023","unstructured":"Cohen KJ, Munjapara V, Aguilera D,  A pilot study omitting radiation in the treatment of children with newly diagnosed WNT-activated medulloblastoma. Clin Cancer Res 2023;29:5031\u20135037."},{"key":"B135","series-title":"J Clin Oncol","first-page":"2685","article-title":"Children\u2019s Oncology Group phase iii trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma","volume":"39","author":"Michalski JM","year":"2021","unstructured":"Michalski JM, Janss AJ, Vezina LG,  Children\u2019s Oncology Group phase iii trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2021;39:2685\u20132697."},{"key":"B136","series-title":"JAMA Oncol","first-page":"1313","article-title":"Efficacy of carboplatin and isotretinoin in children with high-risk medulloblastoma: a randomized clinical trial from the Children\u2019s Oncology Group","volume":"7","author":"Leary SES","year":"2021","unstructured":"Leary SES, Packer RJ, Li Y,  Efficacy of carboplatin and isotretinoin in children with high-risk medulloblastoma: a randomized clinical trial from the Children\u2019s Oncology Group. JAMA Oncol 2021;7:1313\u20131321."},{"key":"B137","series-title":"J Clin Oncol","first-page":"454","article-title":"Superior intellectual outcomes after proton radiotherapy compared with photon radiotherapy for pediatric medulloblastoma","volume":"38","author":"Kahalley LS","year":"2020","unstructured":"Kahalley LS, Peterson R, Ris MD,  Superior intellectual outcomes after proton radiotherapy compared with photon radiotherapy for pediatric medulloblastoma. J Clin Oncol 2020;38:454\u2013461."},{"key":"B138","series-title":"J Pediatr Hematol Oncol","first-page":"e837","article-title":"Neurocognitive outcomes in multiethnic pediatric brain tumor patients treated with proton versus photon radiation","volume":"45","author":"Unnikrishnan S","year":"2023","unstructured":"Unnikrishnan S, Yip AT, Qian AS,  Neurocognitive outcomes in multiethnic pediatric brain tumor patients treated with proton versus photon radiation. J Pediatr Hematol Oncol 2023;45:e837\u2013846."},{"key":"B139","series-title":"Cancer","first-page":"3840","article-title":"Intellectual functioning among case-matched cohorts of children treated with proton or photon radiation for standard-risk medulloblastoma","volume":"127","author":"Eaton BR","year":"2021","unstructured":"Eaton BR, Fong GW, Ingerski LM,  Intellectual functioning among case-matched cohorts of children treated with proton or photon radiation for standard-risk medulloblastoma. Cancer 2021;127:3840\u20133846."},{"key":"B140","series-title":"Int J Radiat Oncol Biol Phys","first-page":"152","article-title":"National Cancer Institute Workshop on Proton Therapy for Children: considerations regarding brainstem injury","volume":"101","author":"Haas-Kogan D","year":"2018","unstructured":"Haas-Kogan D, Indelicato D, Paganetti H,  National Cancer Institute Workshop on Proton Therapy for Children: considerations regarding brainstem injury. Int J Radiat Oncol Biol Phys 2018;101:152\u2013168."},{"key":"B141","series-title":"J Clin Oncol","first-page":"822","article-title":"Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03)","volume":"39","author":"Gajjar A","year":"2021","unstructured":"Gajjar A, Robinson GW, Smith KS,  Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03). J Clin Oncol 2021;39:822\u2013835."},{"key":"B142","series-title":"J Clin Oncol","first-page":"2648","article-title":"Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children\u2019s Oncology Group phase I\/II study","volume":"30","author":"Jakacki RI","year":"2012","unstructured":"Jakacki RI, Burger PC, Zhou T,  Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children\u2019s Oncology Group phase I\/II study. J Clin Oncol 2012;30:2648\u20132653."},{"key":"B143","series-title":"Pediatr Blood Cancer","first-page":"e29031","article-title":"Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: report of a COG randomized phase II screening trial","volume":"68","author":"Levy AS","year":"2021","unstructured":"Levy AS, Krailo M, Chi S,  Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: report of a COG randomized phase II screening trial. Pediatr Blood Cancer 2021;68:e29031."},{"key":"B144","series-title":"Pediatr Blood Cancer","first-page":"e28032","article-title":"Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc bayesian analysis: a european ITCC study","volume":"67","author":"Le Teuff G","year":"2020","unstructured":"Le Teuff G, Castaneda-Heredia A, Dufour C,  Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc bayesian analysis: a european ITCC study. Pediatr Blood Cancer 2020;67:e28032."},{"key":"B145","series-title":"Nat Rev Clin Oncol","first-page":"455","article-title":"Metronomic chemotherapy: new rationale for new directions","volume":"7","author":"Pasquier E","year":"2010","unstructured":"Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010;7:455\u2013465."},{"key":"B146","series-title":"Cancers (Basel)","first-page":"5128","article-title":"Improved long-term survival of patients with recurrent medulloblastoma treated with a \u201cMEMMAT-like\u201d metronomic antiangiogenic approach","volume":"14","author":"Slavc I","year":"2022","unstructured":"Slavc I, Mayr L, Stepien N,  Improved long-term survival of patients with recurrent medulloblastoma treated with a \u201cMEMMAT-like\u201d metronomic antiangiogenic approach. Cancers (Basel) 2022;14:5128."},{"key":"B147","series-title":"J Clin Med","first-page":"1415","article-title":"Retrospective national \u201creal life\u201d experience of the SFCE with the metronomic MEMMAT and MEMMAT-like protocol","volume":"12","author":"Winnicki C","year":"2023","unstructured":"Winnicki C, Leblond P, Bourdeaut F,  Retrospective national \u201creal life\u201d experience of the SFCE with the metronomic MEMMAT and MEMMAT-like protocol. J Clin Med 2023;12:1415."},{"key":"B148","series-title":"JAMA Oncol","first-page":"1688","article-title":"Sustained survival benefit in recurrent medulloblastoma by a metronomic antiangiogenic regimen: a nonrandomized controlled trial","volume":"9","author":"Peyrl A","year":"2023","unstructured":"Peyrl A, Chocholous M, Sabel M,  Sustained survival benefit in recurrent medulloblastoma by a metronomic antiangiogenic regimen: a nonrandomized controlled trial. JAMA Oncol 2023;9:1688\u20131695."},{"key":"B149","series-title":"Pediatr Blood Cancer","first-page":"636","article-title":"A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer","volume":"61","author":"Robison NJ","year":"2014","unstructured":"Robison NJ, Campigotto F, Chi SN,  A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer 2014;61:636\u2013642."},{"key":"B150","series-title":"Cancers (Basel)","first-page":"471","article-title":"Local and systemic therapy of recurrent medulloblastomas in children and adolescents: results of the P-HIT-REZ 2005 study","volume":"14","author":"Gaab C","year":"2022","unstructured":"Gaab C, Adolph JE, Tippelt S,  Local and systemic therapy of recurrent medulloblastomas in children and adolescents: results of the P-HIT-REZ 2005 study. Cancers (Basel) 2022;14:471."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/3\/article-p113.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/3\/article-p113.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/3\/article-p113.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T09:13:47Z","timestamp":1741770827000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/3\/article-p113.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":150,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.0012","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}